Trial Profile

A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2026 Actual primary completion date changed from 13 Feb 2023 to 14 Mar 2023.
18 Aug 2025 According to a Valneva media release, Health Canada's label extension is based on positive six-month adolescent Phase 3 data which the Company reported in May 2024.
01 Apr 2025 According to a Valneva media release, company announced that the European Commission (EC) has granted marketing authorization in Europe for Valnevas single-dose vaccine, IXCHIQ, for the prevention of disease caused by the chikungunya virus in individuals 12 years of age and older.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com